aflibercept Archives | Page 2 of 11

PTAB institutes aflibercept challenges

by Bioblast Editor | Jan 20, 2023 | Biosimilars updates

PTAB instituted two IPR petitions filed by Mylan challenging Regeneron’s US10,130,681 and US10,888,601 patents, which relate to Eylea® (aflibercept). PTAB found that Mylan demonstrated a reasonable likelihood that at least claim 1 of the ‘681 patent and claim 34 of...

Celltrion files IPR petition against Regeneron aflibercept patent

by Bioblast Editor | Jan 17, 2023 | Biosimilars updates

Celltrion filed a petition for inter partes review of Regeneron’s US 10,464,992, relating to Eylea® (aflibercept). Celltrion has alleged the 992 patent is invalid on obviousness and anticipation grounds. In August 2022, Regeneron sued Viatris (Mylan) for...

Coherus Biosciences and Klinge Biopharma commercialisation agreement- biosimilar aflibercept

by Bioblast Editor | Jan 9, 2023 | Biosimilars updates

Coherus Biosciences announced that it has executed a binding term sheet with Klinge Biopharma granting Coherus the exclusive US commercialisation rights to Klinge’s FYB203 (biosimilar aflibercept, targeting Bayer’s Eylea®, developed by Regeneron). Coherus expects to...

Mylan files for IPR of Regeneron’s US 10,130,681 and US 10,888,601 patents

by Bioblast Editor | Jan 7, 2023 | Biosimilars updates

Mylan filed a petition for inter partes review of Regeneron’s US 10,130,681 and US 10,888,601, relating to Eylea® (aflibercept). In August 2022, Regeneron sued Viatris (Mylan) for infringement of 24 patents relating to Eylea, including the ‘681 and ‘601...

Samsung Bioepis files for IPR of Regeneron’s US10,130,681 relating to Eylea® (aflibercept)

by Bioblast Editor | Jan 6, 2023 | Biosimilars updates

Samsung Bioepis filed a petition for inter partes review of Regeneron’s US10,130,681, relating to Eylea® (aflibercept). In August 2022, Regeneron sued Viatris (Mylan) for infringement of 24 patents relating to Eylea, including the ‘681 patent.